Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.76

-2.1%

Dec 30 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2796)	4/28/2010 11:23:04 AM
From: Jibacoa	Read Replies (1) of 3722

BCRX was up 18.06% and is still up 12.82% at present on volume of > 1.27M already about 2x its ADV The stock opened with a small UG and traded above its Apr Hs, but has not been able to test its Jan 13 H of $8.34 <g> bigcharts.marketwatch.com If the stock can close above the Jan H it seems it can get to test the Nov20 DG at the $10 level. <g> BCRX announced that its loss for the 1stQ was $2.6M ($0,06/shr) vs. $9.3M ($0.24/shr) share in 2009. Revenue was up 83% to $26.1M with help from milestone payments from Shionogi after obtaining marketing and manufacturing approval of peramivir in Japan.<g> The estimates according to Thomson/Reuters were for a loss of $0.16/shr on revenue of $19.6 M. BCRX also said that its BCX4208 showed a statistically significant reduction in serum uric acid levels compared to a placebo on a 21-day study was to record the change in serum uric acid concentration after 21 days of treatment in patients with gout.The drug was found to be safe and well-tolerated. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next